García-Gómez L, Hernández-Pérez A, Noé-Díaz V, Riesco-Miranda JA, Jiménez-Ruiz C

Idioma: Ingles.
Referencias bibliográficas: 44
Paginas: 7-16
Archivo PDF: 106.38 Kb.

RESUMEN

Sin resumen.

REFERENCIAS (EN ESTE ARTÍCULO)

1. World Health Organization (WHO). WHO Report on the Global Tobacco Epidemic, 2017. World Health Organization. 2017. p. 1-263. [Last accessed: Jan 5, 2018].

2. Mackay J, Schluger N. Global tobacco epidemic. Tob Epidemic. 2015;42:19-26. [Last accessed: Dec 20, 2017].

3. Reynales-Shigematsu LM, Zavala-Arciniega L, Paz-Ballesteros WC, et al. Encuesta Nacional de Consumo de Drogas, Alcohol y Tabaco, Mexico 2016-2017; 2017.

4. Sansores M, Regalado P, Giraldo B, et al. Guías mexicanas para el tratamiento del tabaquismo. Un consenso nacional de expertos. Neumol Cir Torax. 2005;64:S84-112.

5. de Salud S. Prevención, Diagnostico y Tratamiento del Consumo y Humo Ajeno en el Primer Nivel de Atención. 2009. [Last accessed: Mar 8, 2018].

6. Fiore MC, Jaen CR, Baker T, et al. Treating Tobacco Use and Dependence: 2008 Update. [Last accessed: Feb 21,2018]. USA DHHS; 2008.

7. Aveyard P, Begh R, Parsons A, West R. Brief opportunistic smoking cessation interventions: a systematic review and meta-analysis to compare advice to quit and offer of assistance. Addiction. 2012;107:1066-73.

8. Kotz D, Fidler J, West R. Very low rate and light smokers: smoking patterns and cessation-related behaviour in england, 2006- 11. Addiction. 2012;107:995-1002.

9. Jiloha RC. Biological basis of tobacco addiction: implications for smoking-cessation treatment. Indian J Psychiatry. 2010;52:301-7.

10. Stead LF, Perera R, Bullen C, et al. Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2012; 11:CD000146.

11. Cahill K, Stevens S, Lancaster T. Pharmacological treatments for smoking cessation. JAMA. 2014;311:193-4.

12. Roberts E, Eden Evins A, McNeill A, Robson D. Efficacy and tolerability of pharmacotherapy for smoking cessation in adults with serious mental illness: a systematic review and network metaanalysis. Addiction. 2016;111:599-612.

13. Karam-Hage M, Cinciripini PM, Gritz ER. Tobacco use and cessation for cancer survivors: an overview for clinicians. CA Cancer J Clin. 2014;64:272-90.

14. Leone FT, Evers-Casey S, Toll BA, Vachani A. Treatment of tobacco use in lung cancer: diagnosis and management of lung cancer, 3rd ed: American college of chest physicians evidencebased clinical practice guidelines. Chest. 2013;143:e61S-e77S.

15. Fagerström K, Hughes J. Varenicline in the treatment of tobacco dependence. Neuropsychiatr Dis Treat. 2008;4:353-63.

16. Muramoto ML, Leischow SJ, Sherrill D, Matthews E, Strayer LJ. Randomized, double-blind, placebo-controlled trial of 2 dosages of sustained-release bupropion for adolescent smoking cessation. Arch Pediatr Adolesc Med. 2007;161:1068-74.

17. Cahill K, Lindson-Hawley N, Thomas K, Fanshawe T, Lancaster T. Nicotine Receptor Partial Agonists for Smoking Cessation. [Last accessed: February 2, 2018]. Summary of Findings for the Main Comparison. The Cochrane Library; 2016.

18. Kotz D, Viechtbauer W, Simpson C, et al. Cardiovascular and neuropsychiatric risks of varenicline: a retrospective cohort study. Lancet Respir Med. 2015;3:761-8.

19. Baker TB, Piper ME, Stein JH, et al. Effects of nicotine patch vs varenicline vs combination nicotine replacement therapy on smoking cessation at 26 weeks: a Randomized clinical trial. JAMA. 2016;315:371-9.

20. Garrido P, Prat A, Crespo I, Valverde A, Salvador E. Vacunas para la deshabituación tabáquica. Vacunas. 2012;13:163-70.

21. Zhao Z, Hu Y, Harmon T, et al. Rationalization of a nanoparticlebased nicotine nanovaccine as an effective next-generation nicotine vaccine: a focus on hapten localization. Biomaterials. 2017;138:46-56.

22. Zeigler DF, Roque R, Clegg CH. Construction of an enantiopure bivalent nicotine vaccine using synthetic peptides. PLoS One. 2017;12:e0178835.

23. Thorn JM, Bhattacharya K, Crutcher R, et al. The effect of physicochemical modification on the function of antibodies induced by anti-nicotine vaccine in mice. Vaccines (Basel). 2017;5:e11.

24. Zhao Z, Harris B, Hu Y, et al. Rational incorporation of molecular adjuvants into a hybrid nanoparticle-based nicotine vaccine for immunotherapy against nicotine addiction. Biomaterials. 2018; 155:165-75.

25. Stead LF, Carroll AJ, Lancaster T. Group behaviour therapy programmes for smoking cessation. Cochrane Database Syst Rev. 2017;3:CD001007.

26. Lancaster T, Stead LF. Individual behavioural counselling for smoking cessation. Cochrane Database Syst Rev. 2017;3: CD001292.

27. Stead LF, Koilpillai P, Lancaster T. Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev. 2015;10:CD009670.

28. Hilbert A, Buerger A, Hartmann AS, et al. Psychometric evaluation of the eating disorder examination adapted for children. Eur Eat Disord Rev. 2013;21:330-9.

29. George T. Nicotina y tabaco. In: Tratado de Medicina Interna. [Last accessed: Jan 3,2018]. 2017. p. 9113.

30. Hiscock R, Murray S, Brose LS, et al. Behavioural therapy for smoking cessation: the effectiveness of different intervention types for disadvantaged and affluent smokers. Addict Behav. 2013;38:2787-96.

31. Lindson-Hawley N, Thompson TP, Begh R. Motivational interviewing for smoking cessation. Cochrane Database Syst Rev. 2015;3:CD006936.

32. Ramo DE, Thrul J, Delucchi KL, et al. The tobacco status project (TSP): study protocol for a randomized controlled trial of a facebook smoking cessation intervention for young adults. BMC Public Health. 2015;15:897.

33. Baskerville NB, Azagba S, Norman C, McKeown K, Brown KS. Effect of a digital social media campaign on young adult smoking cessation. Nicotine Tob Res. 2016;18:351-60.

34. Ruscio AC, Muench C, Brede E, Waters AJ. Effect of brief mindfulness practice on self-reported affect, craving, and smoking: a Pilot randomized controlled trial using ecological momentary assessment. Nicotine Tob Res. 2016;18:64-73.

35. Joly B, Perriot J, d’Athis P, et al. Success rates in smoking cessation: psychological preparation plays a critical role and interacts with other factors such as psychoactive substances. PLoS One. 2017;12:e0184800.

36. Abrantes AM, Strong DR, Lloyd-Richardson EE, et al. Regular exercise as a protective factor in relapse following smoking cessation treatment. Am J Addict. 2009;18:100-1.

37. Jiménez-Ruiz CA, Fagerström KO. Smoking cessation treatment for COPD smokers: the role of pharmacological interventions. Monaldi Arch Chest Dis. 2013;79:27-32.

38. Tonstad S, Tønnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.

39. Turk ML, El-Khoury JR. Additional research is needed to improve smoking cessation in developing countries. Addiction. 2014;109:510.

40. Training NC for SC and Local Stop Smoking Services. Service and Delivery Guidance 2014; 2014.

41. Bissell K. Smoking Cessation and Smoke-Free Environments for Tuberculosis Patients. International Union Against Tuberculosis and Lung Disease; 2010.

42. Ministry of Health. New Zealand Guidelines for Helping People to Stop Smoking. [Last accessed: Nov 22, 2017]. 2014. p. 1-9.

43. Kruger J, O’Halloran A, Rosenthal AC, Babb SD, Fiore MC. Receipt of evidence-based brief cessation interventions by health professionals and use of cessation assisted treatments among current adult cigarette-only smokers: national adult tobacco survey, 2009-2010. BMC Public Health. 2016; 16:141.

44. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. Cochrane Database Syst. Rev 2016;3:CD008286.